Mereo BioPharma (MREO) Liabilities and Shareholders Equity (2017 - 2026)

Mereo BioPharma (MREO) has reported Liabilities and Shareholders Equity for 8 consecutive years, with $40.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity fell 40.56% year-over-year to $40.6 million; the TTM figure through Mar 2026 stood at $202.8 million (down 38.48% YoY), while the FY2025 annual figure was $45.9 million, down 39.89% from the prior year.
• Liabilities and Shareholders Equity fell to $40.6 million in Q1 2026 per MREO's latest filing, from $45.9 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $96.1 million in Q2 2024 and bottomed at $40.6 million in Q1 2026.
• Historically, Liabilities and Shareholders Equity has averaged $65.5 million across 4 years, with a median of $64.6 million in 2023.
• Annual changes were most pronounced in 2025 — Liabilities and Shareholders Equity grew 22.14% — and 2026, when it slumped 40.56%.
• Mereo BioPharma's Liabilities and Shareholders Equity stood at $66.5 million in 2023, then advanced by 14.87% to $76.4 million in 2024, then sank by 39.89% to $45.9 million in 2025, then decreased by 11.55% to $40.6 million in 2026.
• Business Quant data shows MREO's Liabilities and Shareholders Equity at $40.6 million in Q1 2026, $45.9 million in Q4 2025, and $53.6 million in Q3 2025.